{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:09:10Z","timestamp":1778936950360,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Classical Hodgkin lymphoma (cHL) is the most frequent lymphoma in children, adolescents and young adults (CAYA). Despite therapeutic advances, around 15% of patients relapse or have refractory (R\/R) disease. Conventional salvage regimens remain effective but are associated with substantial long\u2010term toxicity. Immune checkpoint inhibitors (CPIs), such as nivolumab and pembrolizumab, and the anti\u2010CD30 antibody\u2010drug conjugate brentuximab vedotin (BV) have recently demonstrated encouraging efficacy with improved safety. We conducted a retrospective, multicentre nationwide study to assess the real\u2010world efficacy of CPI in CAYA patients (&lt;18\u2009years) with R\/R cHL treated outside clinical trials in France between August 2015 and May 2023. Twenty\u2010seven patients from 11 centres were included. Median age at CPI initiation was 16\u2009years; 70% had advanced disease. Prior treatments included BV (44%), autologous stem cell transplantation (22%) and allogeneic transplantation (4%). Nivolumab was used in 89%, frequently combined with BV (67%). The overall response rate was 93%, with 63% achieving complete metabolic response. After a median follow\u2010up of 28\u2009months, 3\u2010year progression\u2010free survival and overall survival were 48% and 95%, respectively, and toxicities were manageable. These findings strongly support CPI as a highly effective and well\u2010tolerated treatment option for the CAYA population with R\/R cHL even in heavily pretreated patients.<\/jats:p>","DOI":"10.1111\/bjh.70379","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:30:27Z","timestamp":1771399827000},"page":"1331-1338","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of immune checkpoint inhibitors in paediatric, adolescent and young adults with primary refractory or relapsed classical Hodgkin lymphoma: A national multicentre real\u2010world study"],"prefix":"10.1111","volume":"208","author":[{"given":"Marl\u00e8ne","family":"Pouthier","sequence":"first","affiliation":[{"name":"SIREDO Oncology Center, Institut Curie  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Garnier","sequence":"additional","affiliation":[{"name":"Institut d\u2019H\u00e9matologie et d\u2019Oncologie P\u00e9diatrique, Hospices Civils de Lyon  Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-9588","authenticated-orcid":false,"given":"Amaury","family":"Leruste","sequence":"additional","affiliation":[{"name":"SIREDO Oncology Center, Institut Curie  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Rigaud","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Oncology, Gustave Roussy Universit\u00e9 Paris\u2010Saclay  Villejuif France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Curtillet","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Immunology and Oncology AP\u2010HM, La Timone Children\u2019s Hospital  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Ducassou","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology and Haematology University Hospital of Bordeaux  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyne","family":"Poir\u00e9e","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\u2010Oncology University Hospital Nice  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Emilie","family":"Dourthe","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Immunology Robert Debr\u00e9 University Hospital, AP\u2010HP, Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology University Hospital of Nancy  Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Laure","family":"Couec","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology University Hospital of Nantes  Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacinthe","family":"Bonneau\u2010Lagacherie","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tenon Hospital, AP\u2010HP, Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabah","family":"Boudjemaa","sequence":"additional","affiliation":[{"name":"Department of Pathology Armand Trousseau Hospital, AP\u2010HP, Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Jonca","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tenon Hospital, AP\u2010HP, Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Haouy","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology University Hospital of Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2463-9346","authenticated-orcid":false,"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Immunology Robert Debr\u00e9 University Hospital, AP\u2010HP, Universit\u00e9 Paris Cit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith Landman","family":"Parker","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Trousseau Hospital, AP\u2010HP, Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-8811","authenticated-orcid":false,"given":"Mathieu","family":"Simonin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology Trousseau Hospital, AP\u2010HP, Sorbonne Universit\u00e9  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00470-8"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.177"},{"issue":"1","key":"e_1_2_12_4_1","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet pediatric Hodgkin lymphoma group","volume":"4","author":"Daw S","year":"2020","journal-title":"Hema"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-021-00840-5"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2010.09.005"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0750"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30275-1"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019386"},{"issue":"11","key":"e_1_2_12_12_1","first-page":"2075","article-title":"Nivolumab, brentuximab vedotin, +\/\u2212 bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker\u2010Murray P","year":"2023","journal-title":"Blood"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5627"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(78)90043-7"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229558"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-770719"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70379","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.70379","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:30:02Z","timestamp":1778934602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/bjh.70379"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70379","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"2025-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}